Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors.
Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors.
复制标题
在颅外肿瘤中使用 L-3-[iodine-123]-碘-α-甲基-酪氨酸进行肿瘤成像的可行性。
作者：
P. Jager;E. Franssen;W. Kool;B. Szabo;H. Hoekstra;Hendricus Groen;D. Vries;V. Imhoff;W. Vaalburg;D. Piers
未标记
L-3-[123 I]-碘-α-甲基-酪氨酸（IMT）是一种修饰的氨基酸。据报道，它在脑肿瘤中被大量摄取，反映了氨基酸转运，适用于SPECT。
方法
为了确定脑外的肿瘤是否也可以积聚这种示踪剂，我们将300-450 MBq IMT注射到20名患有不同肿瘤的患者中[5名乳腺癌，4名肺肿瘤（1名良性），2名类癌肝转移，4名软组织肿瘤（1名良性），3名恶性淋巴瘤和2名原发性脑肿瘤]。肿瘤大小为1-12 cm。两名乳腺癌患者在放疗后重复成像。所有病例的组织学检查均可用。在注射后的第一个小时和3小时内进行动态扫描，全身成像和SPECT。分析血浆样品的IMT、游离1231和其他代谢物。
结果
所有原发性肿瘤均可见。肿瘤与背景的比例范围为1.1至3.8平面和1.3至6.2 SPECT图像。肿瘤摄取在第一小时达到峰值。两个肝肿瘤类癌病变表现出没有IMT摄取高于肝脏背景。良性骨炎症过程和局灶性肺血管炎的肿瘤与背景比小于1.2（平面）和1.9（SPECT），并且可以与所有恶性非脑肿瘤的摄取区分开来。IMT从血浆中迅速清除[3.6% +/- 0.6%（平均值+/- s.d.）注射后10分钟注射剂量/升]。存在轻微的体内脱碘（注射后1小时<注射剂量的1%）。正常分布包括脑、肝、脾、肌肉、胰腺区和肠结构中的一些摄取以及肾脏和膀胱中的大量摄取和排泄。
结论
IMT有潜力作为脑外肿瘤的代谢示踪剂。
UNLABELLED
L-3-[123I]-Iodo-alpha-methyl-tyrosine (IMT) is a modified amino acid. It is reported to be avidly taken up in brain tumors, reflecting amino acid transport and is suitable for SPECT.
METHODS
To determine whether tumors outside the brain can also accumulate this tracer, we injected 300-450 MBq IMT into 20 patients with different tumors [5 breast cancers, 4 lung tumors (1 benign), 2 carcinoid liver metastases, 4 soft-tissue tumors (1 benign), 3 malignant lymphomas and 2 primary brain tumors]. Tumor size ranged from 1-12 cm. Imaging was repeated after radiotherapy in two patients with breast cancer. Histology was available in all cases. Dynamic scans, whole-body imaging and SPECT were performed during the first hour and 3 hr after injection. Plasma samples were analyzed for IMT, free 1231 and other metabolites.
RESULTS
All primary tumors were visualized. Tumor-to-background ratios ranged from 1.1 to 3.8 on planar and from 1.3 to 6.2 on SPECT images. Tumor uptake peaked in the first hour. Two carcinoid lesions in the liver tumors exhibited no IMT uptake above liver background. Tumor-to-background ratios in a benign bone inflammatory process and a focal pulmonary vasculitis were less than 1.2 (planar) and 1.9 (SPECT) and could be differentiated from uptake in all malignant nonbrain tumors. IMT was rapidly cleared from the plasma [3.6% +/- 0.6% (mean +/- s.d.) injected dose/liter at 10 min postinjection]. Minor in vivo deiodination was present (<1% of injected dose 1 hr postinjection). No other metabolites were found. Normal distribution consists of some uptake in the brain, liver, spleen, muscles, pancreatic region and intestinal structures and massive uptake and excretion in the kidneys and bladder.
CONCLUSION
IMT has potential as a metabolic tracer in tumors outside the brain.
DOI：
10.1177/0148607192016006569
发表时间：
1992-11
期刊：
JPEN. Journal of parenteral and enteral nutrition
影响因子：
--
作者：
W. Souba;A. J. Pacitti
通讯作者：
W. Souba;A. J. Pacitti